Interrupting Cancer's Growth Signals: The Science of Itovebi
Inavolisib (Itovebi) in India Advances in precision oncology have demonstrated that the size of a therapeutic molecule does not determine its clinical significance. Itovebi (inavolisib) is a notable example of how targeted treatment can influence the course of breast cancer by acting on specific molecular abnormalities that drive disease progression. Understanding its mechanism provides insight into the evolving role of biomarker-guided cancer therapy. Identifying the Molecular Driver The management of breast cancer has increasingly shifted from focusing solely on tumor location and anatomy to understanding the biological mechanisms that support tumor growth. Biomarker testing enables clinicians to identify genetic alterations that may serve as therapeutic targets, allowing treatment strategies to be tailored to the molecular characteristics of an individual's cancer. The Role of PIK3CA Mutations Under normal physiological conditions, the PIK3CA gene provides instructions for prod...
